Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    11-C-0100
Show Display Options
Rank Status Study
1 Recruiting Gemcitabine and CT-011 for Resected Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of the Pancreas;   Neoplasms Pancreatic;   Pancreatic Cancer;   Pancreas Cancer
Interventions: Biological: CT-011;   Drug: Gemcitabine
2 Unknown  Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder
Conditions: Cognitive Impairments;   Schizotypal Personality Disorder
Interventions: Drug: DAR-0100A;   Drug: Placebo
3 Active, not recruiting RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
Conditions: Leukemia;   Acute Lymphocytic Leukemia
Interventions: Drug: Everolimus (RAD001);   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Dexamethasone;   Drug: Mesna;   Drug: Methotrexate;   Drug: Ara-C (Cytarabine);   Drug: Methylprednisone;   Drug: G-CSF
4 Completed
Has Results
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Condition: Relapsing-remitting Multiple Sclerosis
Interventions: Drug: Fingolimod 1.25 mg;   Drug: Fingolimod 0.5 mg;   Drug: Placebo
5 Recruiting Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
Condition: Lupus
Interventions: Drug: BMS-931699;   Drug: Placebo matching BMS-931699

Indicates status has not been verified in more than two years